WO2016142821A2 - Compositions containing a thrombin inhibitor - Google Patents

Compositions containing a thrombin inhibitor Download PDF

Info

Publication number
WO2016142821A2
WO2016142821A2 PCT/IB2016/051233 IB2016051233W WO2016142821A2 WO 2016142821 A2 WO2016142821 A2 WO 2016142821A2 IB 2016051233 W IB2016051233 W IB 2016051233W WO 2016142821 A2 WO2016142821 A2 WO 2016142821A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
pharmaceutically acceptable
dabigatran etexilate
acceptable salts
polymorphs
Prior art date
Application number
PCT/IB2016/051233
Other languages
French (fr)
Other versions
WO2016142821A3 (en
Inventor
Lorraine Angela HILL
Ramesh Cheruvu
Haranatha Babu Balanagu
Seshagiri BEJAWADA
Srinivasulu BALEBOINA
Original Assignee
Alphamed Formulations Pvt. Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphamed Formulations Pvt. Ltd filed Critical Alphamed Formulations Pvt. Ltd
Publication of WO2016142821A2 publication Critical patent/WO2016142821A2/en
Publication of WO2016142821A3 publication Critical patent/WO2016142821A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention relates to the field of oral pharmaceuticals.
  • the invention specifically relates to oral solid dosage forms and methods for the preparation of the same.
  • the present invention further relates to the solid oral dosage forms of the drug Dabigatran etexilate and the methods of the preparation of the same.
  • the active ingredient of the present invention is Dabigatran etexilate mesylate chemically known as " ⁇ - Alanine, N-[[2-[[[4- [ [ [(hexyloxy)carbonyl] amino] iminomethyl] phenyl] amino] methyl] - 1 -methyl- 1 H- benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate" and has an empirical chemical formula C3 4 H 41 N 7 Os ⁇ CH 4 OsS with a structural formula as follows:
  • the product is a known direct thrombin inhibitor. This product has been primarily indicated for the treatment of deep venous thrombosis and pulmonary embolism and prevents their recurrence in previously treated patients. It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
  • WO 98/37075 discloses Dabigatran product as a compound with thrombin inhibiting effect.
  • the invention relates to new disubstituted bicyclic heterocycles of the general formula (I): Ra-A-Het-B-Ar-E.
  • the invention also relates to their tautomers, their stereoisomers, their mixtures, and their salts, which have valuable properties.
  • US 7,932,273 specifically discloses the Form II of Dabigatran etexilate mesylate with specific XRD data.
  • the patent discloses ethyl3-[(2- ⁇ [4- (hexyloxycarbonylaminoiminomethyl)phenylamino] methyl ⁇ - 1 -methyl- 1 H- benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I, II, and the hemihydrate and the use thereof as a pharmaceutical composition.
  • the solubility of the active ingredient in water is only 1.8 mg/ml. Moreover, the active ingredient has a strong pH-dependent solubility that is greatly increased in the acidic environment. This leads to the problem that conventional oral pharmaceutical compositions have large variations in the bioavailability since the solubility of the active ingredient depends on the pH value in the patient's stomach. This is particularly problematic with patients in whom the stomach pH value is changed by physiological variability, illness, or pre-medications (for example, PP inhibitors). There is therefore a need for oral pharmaceutical compositions of the active ingredient Dabigatran etexilate that provide a release that is independent from the pH value of the stomach and thus, provide bioavailability of the active ingredient.
  • US 2003/0181488 discloses a new administration form for the oral application of the active substance ethyl 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl ⁇ -l -methyl- lH-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]- propionate and the pharmacologically acceptable salts thereof in combination with organic acid.
  • compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise Dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.
  • organic acid may cause incompatibilities in the patient.
  • addition of the organic acid restricts the possible amount of active ingredient in an appropriate tablet or capsule. This problem is further exacerbated by the fact that, as a rule, organic acids have only a low buffer capacity so that relatively large amounts of acid have to be added to cause a possible effect on the pH value of the ambience in dissolution of an appropriate tablet.
  • US 2013/0052262 discloses an oral pharmaceutical composition containing a mixture of dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient in combination with an inorganic acidic excipient.
  • dabigatran has a strong pH dependent solubility and thus is effected significantly in patients in whom the stomach pH value is changed by physiological variability, illness, or pre-medications.
  • the present invention attempts to provide an alternative to the use of acids in the pharmaceutical preparation of Dabigatran etexilate for addressing the pH- dependent solubility of Dabigatran by eliminating the use of acids.
  • the objective of the present invention is to provide an oral solid dosage form for Dabigatran etexilate which is devoid of an acid.
  • Another objective of the present invention is to provide an alternative to the use of acids in the pharmaceutical preparation of dabigatran etexilate for addressing the pH-dependent solubility of Dabigatran by eliminating the use of an acid.
  • the present invention provides a solid oral dosage form of a direct thrombin inhibitor or its pharmaceutically acceptable salts or polymorphs which is devoid of an acid.
  • the present invention provides a solid oral dosage form of Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs devoid of an acid.
  • One embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a core, an isolating layer, and a drug containing coating layer.
  • Another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a methacrylic acid copolymer core, an isolating layer and a drug layer; wherein
  • the core comprising methacrylate copolymer or its analogs
  • the isolating layer comprising a polymer
  • the drug layer comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
  • Yet another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a drug core, an isolating layer, and a coating layer.
  • Still another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a drug core, an isolating layer, and a methacrylic acid copolymer coating layer; wherein
  • the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs
  • the present invention provides a solid oral dosage form of a direct thrombin inhibitor or its pharmaceutically acceptable salts or polymorphs which is devoid of an acid, wherein the solid oral dosage form comprises two different particles.
  • the present invention provides a solid oral dosage form of Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs devoid of an acid, wherein the solid oral dosage form comprises two different particles.
  • One embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form is a capsule comprising of two different pellets; wherein a) First pellet comprising a methacrylic acid copolymer or its analogs,
  • Second pellet comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
  • Another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form is comprising two different pellets; wherein
  • Second pellet comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form.
  • Yet another embodiment of the present invention provides that the pharmaceutically acceptable salt of Dabigatran etexilate is Dabigatran etexilate mesylate.
  • Yet another embodiment of the present invention provides that the polymorph of Dabigatran etexilate mesylate used in the present invention is Form I.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprising methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles, and
  • b) outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs.
  • a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles coated with pharmaceutically acceptable polymers, and
  • outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs along with pharmaceutically acceptable excipients.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles, and
  • outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein
  • outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs, and
  • outer capsule comprising methacrylic acid copolymer or its analogs thereof as particles.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs thereof as particles coated with pharmaceutically acceptable polymers, and
  • b) outer capsule comprising methacrylic acid copolymer or its analogs along with pharmaceutically acceptable excipients.
  • a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs thereof, and
  • outer capsule comprising methacrylic acid copolymer or its analogs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
  • Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs thereof as particles coated with pharmaceutically acceptable polymers, and
  • outer capsule comprising methacrylic acid copolymer or its analogs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
  • Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a drug core, an isolating layer, and a coating layer comprising a solubilizing agent; wherein a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
  • Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a drug core, an isolating layer, and a coating layer comprising a solubilizing agent; wherein a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
  • the isolating layer comprising of a polymer
  • the coating layer comprising a solubilizing agent applied by fluid bed processor.
  • Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising solubilizing agent,
  • the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts.
  • Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising solubilizing agent, where in core coated with solubilizing agent using bottom spray granulator,
  • the isolating layer comprising of a polymer
  • the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts applied by fluid bed processor.
  • Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a methacrylic acid copolymer and solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising a methacrylic acid copolymer or its analogs and solubilizing agent,
  • the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts.
  • Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a methacrylic acid copolymer and solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising a methacrylic acid copolymer or its analogs and solubilizing agent, where in core coated with solubilizing agent using bottom spray granulator,
  • the isolating layer comprising of a polymer
  • the present invention avoids the use of an acid in the solid oral dosage form of Dabigatran.
  • the present invention provides an alternative solution by using methacrylic acid copolymers in these solid oral pharmaceutical compositions.
  • the methacrylic acid copolymer used in the present invention can be of different types without limiting to methacrylic acid - ethyl acrylate copolymer, methacrylic acid copolymer Type A, methacrylic acid copolymer Type B, methacrylic acid copolymer Type C, and other ester derivatives of methacrylic acid.
  • the present invention provides an alternative solution by using Solubilizing agent in these solid oral pharmaceutical compositions.
  • the Solubilizing agent used in the present invention can be of different types without limiting to polyoxyethylene-polyoxypropylene (POE-POP) block copolymers, fatty alcohols and fatty alcohol derivatives, and acids, particularly fatty acids and fatty acid derivatives and tocopherol derivatives.
  • Useful fatty acids and alcohols include the C 6 - C 2 2 fatty acids and C 8 -C 22 alcohols, capric acid, caprylic acid, lauric acid, myristic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, behenic acid, and their corresponding pharmaceutically acceptable salts.
  • fatty acid and fatty alcohol derivatives include sodium dioctyl sulfosuccinate, sodium lauryl sulfate, amide esters (e.g., lauric acid diethanolamide, sodium lauryl sarcosinate, lauroyl carnitine, palmitoyl carnitine, and myristoyl carnitine), esters with hydroxy- acids (e.g., sodium stearoyl lactylate); sugar esters, e.g., lauryl lactate, glucose monocaprylate, diglucose monocaprylate, sucrose laurate, sorbitan monolaurate (Arlacel® 20), sorbitan monopalmitate (Span® 40), sorbitan monooleate (Span 80), lower alcohol fatty acid esters e.g., ethyl oleate (Crodamol® EO), isopropyl myristate (Crodamol IPM) and isopropyl palmitate
  • Dabigatran etexilate is acid sensitive.
  • the present invention provides separation of the acidic ingredients from the active ingredient by producing two different pellets.
  • the present invention discloses the isolation of both the pellets by coating the acidic ingredient containing pellet with an isolation layer.
  • the isolation layer may comprise of inert polymers including but not limited to cellulose derivatives like hydroxypropyl methyl cellulose, hydroxylpropyl cellulose, carboxymethyl cellulose, preferably as sodium or calcium salt, hydroxyethyl cellulose, polyvinyl pyrrolidone, co-polymers comprising vinyl pyrrolidone and vinyl acetate units, poly(oxyethylene) alkyl ether, polyethylene glycol, co-block polymers of ethylene oxide, and propylene oxide, polyvinyl alcohol, polyvinyl alcohol derivatives, polyethylene glycol, and polyethylene glycol derivatives.
  • particles as used herein is intended to mean any solid or semi-solid portion of a substance or a composition having defined physical boundaries.
  • particles include, but are not limited to, powder, granules, pellets, beads, minitablets or the like.
  • the granules may be prepared by methods such as, but not limited to, wet granulation, melt granulation, dry granulation or roll compaction or the like.
  • pellets may be prepared using extrusion spheronization and fluidized bed coating process.
  • Non-limiting examples of inert carrier include microcrystalline cellulose, sugar or silicon dioxide.
  • the particles of the present invention, in the powder form may be incorporated in the compositions of the present invention.
  • said first type of particles has a particle size comprised between 50 and 1000 microns and said second type of particles have a particle size comprised between 100 and 1000 microns.
  • the compositions of the present invention comprise from about 5% to about 100% by weight of the mixture of at least two types of particles. Ratio of the first and second types of particles is from about 1 : 99 to about 99: 1.
  • the solid oral dosage form described in various embodiments of the present invention can be further processed into compressed tablets, filled into capsules, used as powder, or as pellets as such. It was surprisingly found that the composition of the present invention exhibits comparable or better dissolution of the drug, compared to the prior art compositions such as Pradaxa.
  • the preferred pharmaceutically acceptable salt of the Dabigatran etexilate is the mesylate salt, i.e. the salt of the methanesulfonic acid and the preferred polymorph of the Dabigatran etexilate mesylate salt is Form I.
  • the present invention further comprises at least one controlled-release polymer.
  • controlled release polymer or its synonymous term “release-rate controlling polymer” refers to a polymer, on account of which a modified release, a retarded/delayed release, a prolonged release or a pulsatile release of the dabigatran active ingredient the pharmaceutical composition is accomplished, relative to a direct or immediate release (also sometimes called conventional release) defined by unaffected dissolution under a given condition.
  • Suitable controlled release polymers include, without being limited thereto, polyvinylpyrrolidone, polymethacrylate, polyvinylacetate, dextranes, starch, cellulose ethers and esters like methyl cellulose, methylethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, or carboxymethylcellulose, polyethyleneoxide, carrageenan, agar, alginic acid, pectin or mixtures thereof, wherein where applicable controlled release types of a specified polymer, as opposed to immediate release types, are selected.
  • the controlled release polymer is present in an amount that allows for the formation of a gel matrix or that allows a the active ingredient to be suitably released in a controlled manner, more preferably by gradual release.
  • the controlled release polymer is Eudragit or ethyl cellulose.
  • controlled release polymer is applied as an over- layer on the second layer comprising dabigatran etexilate or a pharmaceutical acceptable salt thereof.
  • controlled release polymer is comprised in the second layer of the present invention.
  • the pharmaceutical composition according to the present invention further comprises an over-coat.
  • the term "over-coat” used herein refers to a layer which completely covers an object and is applied by film coating.
  • the over-coat can be selected from the group of ready to form dispersion such as OPADRY.
  • the coating dispersion comprises hydrophilic film forming polymer (such as for example low viscosity HPMC, HPC, PVA (polyvinylalcohol) and the like), plastisizer (e.g. PEG), colorants and may optionally include other excipients such as anti-tacking agents.
  • the present invention relates to a capsule comprising one or more units of the pharmaceutical composition of the present invention.
  • Said capsules usually consist of the material selected from hydroxypropylmethylcellulose or gelatine. Further additives like carrageenan, potassium chloride, titanium dioxide and colorants may be present in the capsule shell.
  • the capsules may be packed into a primary packaging having decreased permeability for water vapor.
  • Suitable packaging is selected from high density polyethylene containers, polypropylene containers, aluminum foil blisters and polychloro triflouroethylene blisters.
  • the pellets / particle according to the present invention are compressed into tablets.
  • the composition according to the present invention further comprises pharmaceutically acceptable excipient selected from the group fillers, binders, lubricants, glidants and disintegrants.
  • compositions described herein can further contain fillers such as microcrystalline cellulose, powdered cellulose, compressible sugar, starch (e.g., corn starch or potato starch), pregelatinized starch, fructose, mannitol, dextranes, other sugars such as, siliconized microcrystalline cellulose, calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, tricalcium phosphate, calcium lactate or mixtures thereof.
  • the fillers may be present in the form of a single compound or in the form of a mixture of compounds or co-processed compounds.
  • the compositions described herein may also comprise binders, such as cellulose derivatives (e.g.
  • binder as used herein is defined as an agent able to bind particles which cannot be bound only by a compression force.
  • the binder may be present in the form of a single compound or in the form of a mixture of compounds.
  • compositions described herein may also comprise lubricants.
  • lubricants include but are not limited to stearic acid, talc, hydrogenated vegetable oil (e.g. hydrogenated castor oil), sodium lauryl sulphate, glyceryl behenate, polyethylene glycol, magnesium stearate, calcium stearate and sodium stearyl fumarate.
  • glidant used herein is defined as an agent improving the flow of the powder and thus the filling of the compression chamber of the tablet press. Glidant may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds. In a preferred embodiment the glidant is selected from hydrated earth alkali silicates, preferably talc.
  • compositions described herein may also comprise disintegrants.
  • disintegrant as used herein is an agent accelerating the disintegration of the composition when in contact with a liquid.
  • Preferred disintegrants are polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium carboxymethyl glycolate and sodium bicarbonate.
  • the present invention also provides alternate processes for preparation of a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs devoid of an acid wherein the solid oral dosage form comprises of two different pellets in three different embodiments, each described as follows:
  • One embodiment provides the method comprising the following steps:
  • One embodiment provides the method comprising the following steps:
  • One embodiment provides the method comprising the following steps: a) Preparing first pellets consisting of either methacrylic acid copolymer or its analogs by extrusion and spheronization,
  • Another embodiment of the present invention provides a method of preparation of a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a core, an isolating layer, and a drug layer; wherein
  • a new modified method for preparing pellets is the Hot Melt Extrusion (HME) method where a thermal agent softens or gets melted during the process to obtain pellets.
  • HME Hot Melt Extrusion
  • the equipment used for the Extrusion includes extruders like the ram extruders, screw extruders and gravity fed extruders.
  • the equipment used for the Spheronization includes spheronizers which consists of a wheel with a friction pattern machined on its top surfaceand spinning on a vertical axis within a parallel sided bowl.
  • the Fluidized Bed Process is performed preferably using the Wurster Process.
  • the technology is characterized by the location of a spray nozzle at the bottom of a fluidized bed of solid particles.
  • the particles are moved with a fluidizing air stream that is designed to induce a cyclic particle flow upward past the spray nozzle.
  • the nozzle sprays atomized droplets of coating solution or suspension concurrently with particle flow. Passing particles move upward into an expansion chamber as droplets deposit on their surfaces.
  • the expansion chamber reduces air velocity to allow particles to circulate back to the coating chamber. It also allows particles to further separate from one another temporarily and minimize the potential for particle agglomeration and accretion.
  • the organic solvent or aqueous coating vehicle is evaporated as the particles move into and through the expansion chamber to leave non-volatile coat formulation ingredients on the particle surface as part of the developing film coat.
  • the solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs devoid of an acid described in the present invention may further include acceptable pharmaceutical ingredients like such as e.g. fillers, lubricants, flow control agents, release agents, and disintegrants which include but are not limited to micro crystalline cellulose, lactose, hydroxypropyl methyl cellulose, hydroxylpropyl cellulose, sodium starch glycolate, croscarmellose sodium, crospovidone, magnesium stearate, sodium stearylfumarate, stearic acid, dimethicone, Talc, Isopropanol, etc.
  • acceptable pharmaceutical ingredients like such as e.g. fillers, lubricants, flow control agents, release agents, and disintegrants which include but are not limited to micro crystalline cellulose, lactose, hydroxypropyl methyl cellulose, hydroxylpropyl cellulose, sodium starch glycolate, croscarmellose sodium, crospovid
  • Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
  • Drug layered pellets were filled in size 0 HPMC capsules.
  • Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
  • the seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
  • Sugar spheres were coated using Sodium lauryl sulphate in purified water in bottom spray granulator. Seal coating Sodium lauryl sulphate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
  • the seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
  • Substrate - 1 Drug Layering Sugar spheres were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
  • Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
  • Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
  • the seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
  • Drug layered pellets were filled in size Oel HPMC capsules.
  • Sugar spheres were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
  • Capsule filling The size 4 capsule was kept in size 0 capsule followed by filled with the API pellets.
  • Dissolution profiles of the solid oral dosage forms of the present invention in comparison with Pradaxa® are given below :

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the field of oral pharmaceuticals. The invention specifically relates to oral solid dosage forms and methods for the preparation of the same. The present invention further relates to the solid oral dosage forms of the drug Dabigatran etexilate and the methods of the preparation of the same.

Description

COMPOSITIONS CONTAINING A THROMBIN INHIBITOR
FIELD OF INVENTION
The present invention relates to the field of oral pharmaceuticals. The invention specifically relates to oral solid dosage forms and methods for the preparation of the same. The present invention further relates to the solid oral dosage forms of the drug Dabigatran etexilate and the methods of the preparation of the same.
BACKGROUND OF INVENTION
The active ingredient of the present invention is Dabigatran etexilate mesylate chemically known as "β- Alanine, N-[[2-[[[4- [ [ [(hexyloxy)carbonyl] amino] iminomethyl] phenyl] amino] methyl] - 1 -methyl- 1 H- benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfonate" and has an empirical chemical formula C34H41N7Os · CH4OsS with a structural formula as follows:
Figure imgf000002_0001
The product is a known direct thrombin inhibitor. This product has been primarily indicated for the treatment of deep venous thrombosis and pulmonary embolism and prevents their recurrence in previously treated patients. It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. WO 98/37075 (US 6,087,380) discloses Dabigatran product as a compound with thrombin inhibiting effect. The invention relates to new disubstituted bicyclic heterocycles of the general formula (I): Ra-A-Het-B-Ar-E. The invention also relates to their tautomers, their stereoisomers, their mixtures, and their salts, which have valuable properties. The compounds of the above general formula (I), in which E is a cyano group, thus represent valuable intermediate products for the production of the other compounds of the general formula (I). Furthermore, the compounds of the above general formula (I), in which E stands for a RbNH-C(=NH)-group, have valuable pharmacological properties, in particular in inhibiting thrombin and prolonging thrombin time.
US 7,932,273 specifically discloses the Form II of Dabigatran etexilate mesylate with specific XRD data. The patent discloses ethyl3-[(2-{ [4- (hexyloxycarbonylaminoiminomethyl)phenylamino] methyl } - 1 -methyl- 1 H- benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I, II, and the hemihydrate and the use thereof as a pharmaceutical composition.
The solubility of the active ingredient in water is only 1.8 mg/ml. Moreover, the active ingredient has a strong pH-dependent solubility that is greatly increased in the acidic environment. This leads to the problem that conventional oral pharmaceutical compositions have large variations in the bioavailability since the solubility of the active ingredient depends on the pH value in the patient's stomach. This is particularly problematic with patients in whom the stomach pH value is changed by physiological variability, illness, or pre-medications (for example, PP inhibitors). There is therefore a need for oral pharmaceutical compositions of the active ingredient Dabigatran etexilate that provide a release that is independent from the pH value of the stomach and thus, provide bioavailability of the active ingredient.
US 2003/0181488 discloses a new administration form for the oral application of the active substance ethyl 3-[(2-{ [4-(hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-l -methyl- lH-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]- propionate and the pharmacologically acceptable salts thereof in combination with organic acid.
WO 2013/124340 discloses compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise Dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.
The use of organic acid to address this issue may cause incompatibilities in the patient. Moreover, the addition of the organic acid restricts the possible amount of active ingredient in an appropriate tablet or capsule. This problem is further exacerbated by the fact that, as a rule, organic acids have only a low buffer capacity so that relatively large amounts of acid have to be added to cause a possible effect on the pH value of the ambience in dissolution of an appropriate tablet.
US 2013/0052262 discloses an oral pharmaceutical composition containing a mixture of dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient in combination with an inorganic acidic excipient.
It can be comprehended from the background art that dabigatran has a strong pH dependent solubility and thus is effected significantly in patients in whom the stomach pH value is changed by physiological variability, illness, or pre-medications.
It is also understood from the prior art that organic and inorganic acids are used to address the solubility issue of dabigatran. However, it has been observed that organic acids may cause incompatibilities in patients or can limit the amount of drug used in the pharmaceutical preparation due to their intrinsic properties while these limitations are not observed in case of inorganic acids. However, it has been observed that Dabigatran is acid sensitive and hence, there is a need to overcome this incompatibility in the formulations containing the inorganic acid.
The present invention attempts to provide an alternative to the use of acids in the pharmaceutical preparation of Dabigatran etexilate for addressing the pH- dependent solubility of Dabigatran by eliminating the use of acids.
OBJECTIVE OF INVENTION
The objective of the present invention is to provide an oral solid dosage form for Dabigatran etexilate which is devoid of an acid.
Another objective of the present invention is to provide an alternative to the use of acids in the pharmaceutical preparation of dabigatran etexilate for addressing the pH-dependent solubility of Dabigatran by eliminating the use of an acid.
SUMMARY OF INVENTION
The present invention provides a solid oral dosage form of a direct thrombin inhibitor or its pharmaceutically acceptable salts or polymorphs which is devoid of an acid.
The present invention provides a solid oral dosage form of Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs devoid of an acid.
One embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a core, an isolating layer, and a drug containing coating layer.
Another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a methacrylic acid copolymer core, an isolating layer and a drug layer; wherein
a) the core comprising methacrylate copolymer or its analogs,
b) the isolating layer comprising a polymer, c) the drug layer comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
Yet another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a drug core, an isolating layer, and a coating layer.
Still another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a drug core, an isolating layer, and a methacrylic acid copolymer coating layer; wherein
a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
b) the isolating layer comprising a coating composition comprising of a polymer, c) the coating layer comprising of methacrylic acid copolymer or its analogs. The present invention provides a solid oral dosage form of a direct thrombin inhibitor or its pharmaceutically acceptable salts or polymorphs which is devoid of an acid, wherein the solid oral dosage form comprises two different particles.
The present invention provides a solid oral dosage form of Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs devoid of an acid, wherein the solid oral dosage form comprises two different particles.
One embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form is a capsule comprising of two different pellets; wherein a) First pellet comprising a methacrylic acid copolymer or its analogs,
b) Second pellet comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs. Another embodiment of the present invention provides a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form is comprising two different pellets; wherein
a) First pellet comprising a methacrylic acid copolymer or its analogs which is coated with an isolating layer,
b) Second pellet comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form.
Yet another embodiment of the present invention provides that the pharmaceutically acceptable salt of Dabigatran etexilate is Dabigatran etexilate mesylate.
Yet another embodiment of the present invention provides that the polymorph of Dabigatran etexilate mesylate used in the present invention is Form I.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprising methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles, and
b) outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs. Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles coated with pharmaceutically acceptable polymers, and
b) outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs along with pharmaceutically acceptable excipients.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles, and
b) outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein
a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles coated with pharmaceutically acceptable polymers, and
b) outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs, and
b) outer capsule comprising methacrylic acid copolymer or its analogs thereof as particles.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs thereof as particles coated with pharmaceutically acceptable polymers, and
b) outer capsule comprising methacrylic acid copolymer or its analogs along with pharmaceutically acceptable excipients. Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs thereof, and
b) outer capsule comprising methacrylic acid copolymer or its analogs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
Yet another embodiment of the present invention provides a capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprises two different types of solid unit dosage forms filled into it; wherein one of the solid unit dosage form comprises methacrylic acid copolymer or its analogs thereof and the other solid dosage form comprising Dabigatran etexilate; wherein the two different types of solid unit dosage forms are an inner capsule and an outer capsule, i.e., capsule-in-capsule dosage form; wherein a) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs thereof as particles coated with pharmaceutically acceptable polymers, and
b) outer capsule comprising methacrylic acid copolymer or its analogs along with pharmaceutically acceptable excipients, coated with pharmaceutically acceptable polymers.
Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a drug core, an isolating layer, and a coating layer comprising a solubilizing agent; wherein a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
b) the isolating layer,
c) the coating layer comprising a solubilizing agent. Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a drug core, an isolating layer, and a coating layer comprising a solubilizing agent; wherein a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
b) the isolating layer comprising of a polymer,
c) the coating layer comprising a solubilizing agent applied by fluid bed processor.
Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising solubilizing agent,
b) the isolating layer,
c) the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts.
Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising solubilizing agent, where in core coated with solubilizing agent using bottom spray granulator,
b) the isolating layer comprising of a polymer,
c) the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts applied by fluid bed processor.
Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a methacrylic acid copolymer and solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising a methacrylic acid copolymer or its analogs and solubilizing agent,
b) the isolating layer,
c) the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts.
Yet another embodiment of the present invention provides a method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises an inner core comprising a methacrylic acid copolymer and solubilizing agent, an isolating layer, and a drug coating layer; wherein a) the core comprising a methacrylic acid copolymer or its analogs and solubilizing agent, where in core coated with solubilizing agent using bottom spray granulator,
b) the isolating layer comprising of a polymer,
c) the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts applied by fluid bed processor. DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the present invention avoids the use of an acid in the solid oral dosage form of Dabigatran.
In another embodiment, the present invention provides an alternative solution by using methacrylic acid copolymers in these solid oral pharmaceutical compositions. The methacrylic acid copolymer used in the present invention can be of different types without limiting to methacrylic acid - ethyl acrylate copolymer, methacrylic acid copolymer Type A, methacrylic acid copolymer Type B, methacrylic acid copolymer Type C, and other ester derivatives of methacrylic acid. In another embodiment, the present invention provides an alternative solution by using Solubilizing agent in these solid oral pharmaceutical compositions. The Solubilizing agent used in the present invention can be of different types without limiting to polyoxyethylene-polyoxypropylene (POE-POP) block copolymers, fatty alcohols and fatty alcohol derivatives, and acids, particularly fatty acids and fatty acid derivatives and tocopherol derivatives. Useful fatty acids and alcohols include the C6- C22 fatty acids and C8-C22 alcohols, capric acid, caprylic acid, lauric acid, myristic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, behenic acid, and their corresponding pharmaceutically acceptable salts. Examples of fatty acid and fatty alcohol derivatives include sodium dioctyl sulfosuccinate, sodium lauryl sulfate, amide esters (e.g., lauric acid diethanolamide, sodium lauryl sarcosinate, lauroyl carnitine, palmitoyl carnitine, and myristoyl carnitine), esters with hydroxy- acids (e.g., sodium stearoyl lactylate); sugar esters, e.g., lauryl lactate, glucose monocaprylate, diglucose monocaprylate, sucrose laurate, sorbitan monolaurate (Arlacel® 20), sorbitan monopalmitate (Span® 40), sorbitan monooleate (Span 80), lower alcohol fatty acid esters e.g., ethyl oleate (Crodamol® EO), isopropyl myristate (Crodamol IPM) and isopropyl palmitate (Crodamol IPP), esters with propylene glycol [e.g., propylene glycol monolaurate (Lauroglycol™ FCC), propylene glycol ricinoleate (Propymuls®), propylene glycol monooleate (Myverol® P-06), propylene glycol monocaprylate (Capryol® 90), propylene glycol dicaprylate/dicaprate (Captex® 200) and propylene glycol dioctanoate (Captex 800), esters with glycerol e.g., glyceryl monooleate, glyceryl ricinoleate, glyceryl laurate, glyceryl dilaurate (Capmul® GDL), glyceryl dioleate (Capmul GDO), glycerol monolinoleate (Maisine®), glyceryl mono/dioleate (Capmul GMO-K), glyceryl caprylate/caprate (Capmul MCM), caprylic acid mono/diglycerides (Imwitor® 988), mono- and di- acetylated monoglycerides (Myvacet® 9-45), triglycerides, e.g., corn oil, almond oil, soybean oil, coconut oil, castor oil, hydrogenated castor oil, hydrogenated coconut oil, Pureco 100, Hydrokote AP5, Captex 300, 350, Miglyol® 812, Miglyol 818 and Gelucire® 33/01), mixtures of propylene glycol esters and glycerol esters e.g., mixtures of oleic acid esters of propylene glycol and glycerol (Arlacel 186), and polyglycerized fatty acids such as polyglyceryl oleate (Plurol® Oleique), polyglyceryl-2 dioleate (Nikko DGDO), polyglyceryl-10 trioleate, polyglyceryl-10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10 oleate (Nildcol Decaglyn 1-0), and polyglyceryl-10 mono dioleate (Caprol® PEG 860).
Dabigatran etexilate is acid sensitive. Hence, in another embodiment, the present invention provides separation of the acidic ingredients from the active ingredient by producing two different pellets.
Further, in another embodiment, the present invention discloses the isolation of both the pellets by coating the acidic ingredient containing pellet with an isolation layer. The isolation layer may comprise of inert polymers including but not limited to cellulose derivatives like hydroxypropyl methyl cellulose, hydroxylpropyl cellulose, carboxymethyl cellulose, preferably as sodium or calcium salt, hydroxyethyl cellulose, polyvinyl pyrrolidone, co-polymers comprising vinyl pyrrolidone and vinyl acetate units, poly(oxyethylene) alkyl ether, polyethylene glycol, co-block polymers of ethylene oxide, and propylene oxide, polyvinyl alcohol, polyvinyl alcohol derivatives, polyethylene glycol, and polyethylene glycol derivatives.
The term "particle" as used herein is intended to mean any solid or semi-solid portion of a substance or a composition having defined physical boundaries. Examples of particles include, but are not limited to, powder, granules, pellets, beads, minitablets or the like. The granules may be prepared by methods such as, but not limited to, wet granulation, melt granulation, dry granulation or roll compaction or the like. In an embodiment of the present invention, pellets may be prepared using extrusion spheronization and fluidized bed coating process. Non-limiting examples of inert carrier include microcrystalline cellulose, sugar or silicon dioxide. In yet another embodiment, the particles of the present invention, in the powder form, may be incorporated in the compositions of the present invention.
In an embodiment of the present invention said first type of particles has a particle size comprised between 50 and 1000 microns and said second type of particles have a particle size comprised between 100 and 1000 microns. The compositions of the present invention comprise from about 5% to about 100% by weight of the mixture of at least two types of particles. Ratio of the first and second types of particles is from about 1 : 99 to about 99: 1.
The solid oral dosage form described in various embodiments of the present invention can be further processed into compressed tablets, filled into capsules, used as powder, or as pellets as such. It was surprisingly found that the composition of the present invention exhibits comparable or better dissolution of the drug, compared to the prior art compositions such as Pradaxa.
In one embodiment of the present invention the preferred pharmaceutically acceptable salt of the Dabigatran etexilate is the mesylate salt, i.e. the salt of the methanesulfonic acid and the preferred polymorph of the Dabigatran etexilate mesylate salt is Form I.
In another aspect the present invention further comprises at least one controlled-release polymer. The term "controlled release polymer", or its synonymous term "release-rate controlling polymer", refers to a polymer, on account of which a modified release, a retarded/delayed release, a prolonged release or a pulsatile release of the dabigatran active ingredient the pharmaceutical composition is accomplished, relative to a direct or immediate release (also sometimes called conventional release) defined by unaffected dissolution under a given condition. Suitable controlled release polymers include, without being limited thereto, polyvinylpyrrolidone, polymethacrylate, polyvinylacetate, dextranes, starch, cellulose ethers and esters like methyl cellulose, methylethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, or carboxymethylcellulose, polyethyleneoxide, carrageenan, agar, alginic acid, pectin or mixtures thereof, wherein where applicable controlled release types of a specified polymer, as opposed to immediate release types, are selected. It is preferably that the controlled release polymer is present in an amount that allows for the formation of a gel matrix or that allows a the active ingredient to be suitably released in a controlled manner, more preferably by gradual release. According to a further preferred embodiment, the controlled release polymer is Eudragit or ethyl cellulose.
In a preferred embodiment controlled release polymer is applied as an over- layer on the second layer comprising dabigatran etexilate or a pharmaceutical acceptable salt thereof. Alternatively, controlled release polymer is comprised in the second layer of the present invention. In a preferred embodiment the pharmaceutical composition according to the present invention further comprises an over-coat. The term "over-coat" used herein refers to a layer which completely covers an object and is applied by film coating. The over-coat can be selected from the group of ready to form dispersion such as OPADRY. The coating dispersion comprises hydrophilic film forming polymer (such as for example low viscosity HPMC, HPC, PVA (polyvinylalcohol) and the like), plastisizer (e.g. PEG), colorants and may optionally include other excipients such as anti-tacking agents.
In another aspect the present invention relates to a capsule comprising one or more units of the pharmaceutical composition of the present invention. Said capsules usually consist of the material selected from hydroxypropylmethylcellulose or gelatine. Further additives like carrageenan, potassium chloride, titanium dioxide and colorants may be present in the capsule shell.
The capsules may be packed into a primary packaging having decreased permeability for water vapor. Suitable packaging is selected from high density polyethylene containers, polypropylene containers, aluminum foil blisters and polychloro triflouroethylene blisters.
In another aspect the present invention the pellets / particle according to the present invention are compressed into tablets. In a preferred embodiment the composition according to the present invention further comprises pharmaceutically acceptable excipient selected from the group fillers, binders, lubricants, glidants and disintegrants.
The pharmaceutical compositions described herein can further contain fillers such as microcrystalline cellulose, powdered cellulose, compressible sugar, starch (e.g., corn starch or potato starch), pregelatinized starch, fructose, mannitol, dextranes, other sugars such as, siliconized microcrystalline cellulose, calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, tricalcium phosphate, calcium lactate or mixtures thereof. The fillers may be present in the form of a single compound or in the form of a mixture of compounds or co-processed compounds. The compositions described herein may also comprise binders, such as cellulose derivatives (e.g. hypromellose, hydroxypropylcellulose, methylcellulose and sodium carboxymethylcellulose), polyvinylpyrrolidone, gelatin, lactose, sucrose, acacia, polyethylene glycol, polymethacrylates, hydroxypropylcellulose, pregelatinized starch and sodium alginate. The term "binder" as used herein is defined as an agent able to bind particles which cannot be bound only by a compression force. The binder may be present in the form of a single compound or in the form of a mixture of compounds.
The compositions described herein may also comprise lubricants. Various suitable lubricants include but are not limited to stearic acid, talc, hydrogenated vegetable oil (e.g. hydrogenated castor oil), sodium lauryl sulphate, glyceryl behenate, polyethylene glycol, magnesium stearate, calcium stearate and sodium stearyl fumarate. The term "glidant" used herein is defined as an agent improving the flow of the powder and thus the filling of the compression chamber of the tablet press. Glidant may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds. In a preferred embodiment the glidant is selected from hydrated earth alkali silicates, preferably talc.
The compositions described herein may also comprise disintegrants. The term disintegrant as used herein is an agent accelerating the disintegration of the composition when in contact with a liquid. Preferred disintegrants are polyvinylpyrrolidone, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium carboxymethyl glycolate and sodium bicarbonate.
The present invention also provides alternate processes for preparation of a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs devoid of an acid wherein the solid oral dosage form comprises of two different pellets in three different embodiments, each described as follows:
I. One embodiment provides the method comprising the following steps:
a) Preparing first pellets consisting of either methacrylic acid copolymer or its analogs by extrusion and spheronization,
b) Preparing the second pellet consisting of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs by extrusion and spheronization.
II. One embodiment provides the method comprising the following steps:
a) Preparing first pellets consisting of either methacrylic acid copolymer or its analogs by extrusion and spheronization,
b) Isolating the first pellet by coating with an isolating layer comprising of cellulosic derivatives by the fluidized bed process,
c) Preparing the second pellet consisting of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs by extrusion and spheronization.
III. One embodiment provides the method comprising the following steps: a) Preparing first pellets consisting of either methacrylic acid copolymer or its analogs by extrusion and spheronization,
b) Isolating the first pellet by coating with an isolating layer comprising of cellulosic derivatives by the fluidized bed process,
c) Preparing the second pellet consisting of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs by spraying the drug onto an inert core by the fluidized bed process.
Another embodiment of the present invention provides a method of preparation of a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a core, an isolating layer, and a drug layer; wherein
d) Preparing the core comprising either the drug or the methacrylate copolymer or its analogs is prepared by extrusion and spheronization,
e) Applying the isolating layer comprising a coating composition comprising of a polymer by the fluidized bed process,
a) Applying the coating layer comprising of either Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs or methacrylic acid copolymer or its analogs by the fluidized bed process.
The techniques and preparation methods followed in all of the above methods mentioned above are described in detail as follows:
A new modified method for preparing pellets is the Hot Melt Extrusion (HME) method where a thermal agent softens or gets melted during the process to obtain pellets.
The equipment used for the Extrusion includes extruders like the ram extruders, screw extruders and gravity fed extruders. The equipment used for the Spheronization includes spheronizers which consists of a wheel with a friction pattern machined on its top surfaceand spinning on a vertical axis within a parallel sided bowl.
The Fluidized Bed Process is performed preferably using the Wurster Process. The technology is characterized by the location of a spray nozzle at the bottom of a fluidized bed of solid particles. The particles are moved with a fluidizing air stream that is designed to induce a cyclic particle flow upward past the spray nozzle. The nozzle sprays atomized droplets of coating solution or suspension concurrently with particle flow. Passing particles move upward into an expansion chamber as droplets deposit on their surfaces. The expansion chamber reduces air velocity to allow particles to circulate back to the coating chamber. It also allows particles to further separate from one another temporarily and minimize the potential for particle agglomeration and accretion. The organic solvent or aqueous coating vehicle is evaporated as the particles move into and through the expansion chamber to leave non-volatile coat formulation ingredients on the particle surface as part of the developing film coat.
The solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs devoid of an acid described in the present invention may further include acceptable pharmaceutical ingredients like such as e.g. fillers, lubricants, flow control agents, release agents, and disintegrants which include but are not limited to micro crystalline cellulose, lactose, hydroxypropyl methyl cellulose, hydroxylpropyl cellulose, sodium starch glycolate, croscarmellose sodium, crospovidone, magnesium stearate, sodium stearylfumarate, stearic acid, dimethicone, Talc, Isopropanol, etc. The following examples describes the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not limitative and relate to solutions which have been particularly effective on a bench scale.
EXAMPLES: EXAMPLE 1: S.No INGREDIENTS AMOUNT (mg)
Methacrylate copolymer coating
1. Sugar spheres 60.00
2. Methacrylate copolymer 177.14
3. Polyethylene glycol 17.72
4. Talc 4.00
5. Purified water Qs
Isolating layer
6. Hydroxypropyl methylcellulose E5 4.46
7. Dimethicone 0.08
8. Talc 1.36
9. Water Qs
Drug layering
10. Dabigatran Etexilate Mesilate 172.95
11. Hydroxypropyl cellulose 34.59
12. Talc 27.70
13. Isopropyl alcohol Qs
14. Empty Capsule Size O
Capsule fill weight 500.00 mg
Manufacturing procedure Methacrylate copolymer coating
Sugar spheres were coated using Methacrylate copolymer, Polyethylene glycol and talc in purified water in bottom spray granulator.
Seal coating Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
Drug Layering
The seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA. Capsule filling:
Drug layered pellets were filled in size 0 HPMC capsules.
EXAMPLE 2:
Figure imgf000022_0001
8. Talc 3.48
9. Water Qs
Drug layering
10. Dabigatran Etexilate Mesilate 172.95
11. Hydroxypropyl cellulose 34.59
12. Talc 27.70
13. Isopropyl alcohol Qs
14. Empty Capsule Size Oel
Capsule fill weight 502.50 mg
Manufacturing procedure
Methacrylate copolymer coating
Sugar spheres were coated using Methacrylate copolymer, Polyethylene glycol and talc in purified water in bottom spray granulator.
Seal coating
Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
Drug Layering The seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
EXAMPLE 3: S.No INGREDIENTS AMOUNT (mg)
1. Sugar spheres 35.00
2. Sodium lauryl sulphate 20.00
3. Purified water Qs
Isolating layer
4. Hydroxypropyl methylcellulose E5 1.35
5. Dimethicone 0.03
6. Talc 1.98
7. Water Qs
Drug layering
8. Dabigatran Etexilate Mesilate 172.95
9. Hydroxypropyl cellulose 34.59
10. Talc 27.70
11. Isopropyl alcohol Qs
12. Empty Capsule Size O
Capsule fill weight 293.6 mg
Manufacturing procedure
Sugar spheres were coated using Sodium lauryl sulphate in purified water in bottom spray granulator. Seal coating Sodium lauryl sulphate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
Drug Layering
The seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
Capsule filling:
Drug layered pellets were filled in size 0 HPMC capsules. EXAMPLE 4:
Figure imgf000025_0001
Isolating layer
11. Hydroxypropyl methylcellulose E5 4.46
12. Dimethicone 0.08
13. Talc 1.36
14. Water Qs
15. Empty Capsule Size Oel
Capsule fill weight 550.00 mg
Manufacturing procedure Substrate - 1 Drug Layering Sugar spheres were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
Substrate - 2
Methacrylate copolymer coating
Sugar spheres were coated using Methacrylate copolymer, Polyethylene glycol and talc in purified water in bottom spray granulator.
Seal coating
Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
Capsule filling: Pellets of substrate - 1 & 2 were filled in size Oel HPMC capsules. EXAMPLE 5:
Figure imgf000027_0001
Manufacturing procedure Methacrylate copolymer coating
Sugar spheres were coated using Methacrylate copolymer, sodium lauryl sulphate, Polyethylene glycol and talc in purified water in bottom spray granulator.
Seal coating
Methacrylate pellets were loaded in fluid bed processor and seal coated using Hydroxypropyl methylcellulose, Dimethicone and talc in purified water.
Drug Layering The seal coated pellets were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
Capsule filling:
Drug layered pellets were filled in size Oel HPMC capsules.
EXAMPLE 6:
Figure imgf000028_0001
Outer capsule composition
7. Sugar spheres 15.00
8. Dabigatran Etexilate Mesilate 172.95
9. Hydroxypropyl cellulose 34.55
10. Talc 27.70
11. Isopropyl alcohol Qs
12. Empty Capsule Size O
Outer capsule fill weight 250.20 mg
Inner capsule fill weight 216.00 mg
Manufacturing procedure Inner Capsule
Sugar spheres were coated using Methacrylate copolymer, Polyethylene glycol and talc in purified water in bottom spray granulator.
Outer Capsule
Sugar spheres were loaded in fluid bed processor and coated with Dabigatran etexilate mesilate, hydroxypropyl cellulose and talc in IPA.
Capsule filling: The size 4 capsule was kept in size 0 capsule followed by filled with the API pellets.
Dissolution profiles of the solid oral dosage forms of the present invention in comparison with Pradaxa® are given below :
The dissolution profile was performed in 900 ml of 0.0 IN HC1 using USP-I rotating basket apparatus set at lOOrpm. Time (Min) Pradaxa® Example 1 Example 3 Example 4
(Australia
reference)
(Lot: 406467)
% Drug release 0 18 27 61 21 5 76 86 84 30 0 95 96 88 35 0 99 103 91 43 5 99 106 91 55

Claims

We Claim:
1. A solid oral dosage form of a direct thrombin inhibitor or its pharmaceutically acceptable salts or polymorphs which is devoid of an acid.
2. The solid dosage form as claimed in claim 1 wherein the direct thrombin inhibitor is Dabigatran etexilate.
3. The solid dosage form as claimed in claim 2 wherein the composition comprises methacrylic acid copolymers.
4. The methacrylic acid copolymer as claimed in claim 3 is selected from methacrylic acid - ethyl acrylate copolymer, methacrylic acid copolymer Type A, methacrylic acid copolymer Type B, methacrylic acid copolymer Type C, and other ester derivatives of methacrylic acid.
5. The solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a core, an isolating layer, and a drug containing coating layer.
6. The solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a core, an isolating layer and a drug layer; wherein
a) the core comprising methacrylate copolymer or its analogs,
b) the isolating layer comprising a coating composition comprising of a polymer, c) the drug layer comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
7. A solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprises a drug core, an isolating layer, and a coating layer.
8. The solid oral dosage form of Dabigatran etexilate claimed in claim 7 wherein the solid oral dosage form comprising a drug core, an isolating layer, and a coating layer; wherein
a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
b) the isolating layer comprising a coating composition comprising of a polymer, c) the coating layer comprising of methacrylic acid copolymer or its analogs.
9. A solid oral dosage form of a direct thrombin inhibitor or its pharmaceutically acceptable salts or polymorphs which is devoid of an acid, wherein the solid oral dosage form comprises two different particles wherein,
a) First pellet comprising a methacrylic acid copolymer or its analogs,
b) Second pellet comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
10. The solid oral dosage form of Dabigatran etexilate claimed in claim 9 wherein the solid oral dosage form is comprising two different pellets wherein, a) First pellet comprising a methacrylic acid copolymer or its analogs which is coated with an isolating layer,
b) Second pellet comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs.
11. A capsule dosage form comprising a Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs; wherein the capsule comprising two different types of solid unit dosage forms filled into it; wherein the two different types of solid unit dosage forms are in an inner capsule and an outer capsule, i.e., capsule- in-capsule dosage form.
12. The capsule as claimed in claim 11 wherein
a) inner capsule comprising methacrylic acid copolymer or its analogs thereof as particles, and
b) outer capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs.
13. The capsule as claimed in claim 11 wherein
c) inner capsule comprising Dabigatran etexilate or its pharmaceutically acceptable salts or polymorphs, and
d) outer capsule comprising methacrylic acid copolymer or its analogs thereof as particles.
14. A method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising a drug core, an isolating layer, and a coating layer containing a solubilizing agent; wherein a) the drug core comprising of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs,
d) the isolating layer,
e) the coating layer comprising a solubilizing agent.
15. A method of preparing a solid oral dosage form of Dabigatran etexilate and its pharmaceutically acceptable salts or polymorphs wherein the solid oral dosage form comprising an inner core comprising a solubilizing agent, an isolating layer, and a drug coating layer; wherein
a) the core comprising solubilizing agent,
b) the isolating layer,
c) the coating layer comprising Dabigatran etexilate and its pharmaceutically acceptable salts.
16. The method as claimed in claims 14 and 15 wherein the isolating layer comprises a polymer.
17. The method as claimed in claims 14 and 15 wherein the coating layer is applied by a fluid bed processer.
18. The method as claimed in claims 14 and 15 wherein the Solubilizing agent is selected from polyoxyethylene-polyoxypropylene (POE-POP) block copolymers, fatty alcohols and fatty alcohol derivatives, and acids, particularly fatty acids and fatty acid derivatives and tocopherol derivatives.
19. The fatty acids and alcohols as claimed in claim 18 include the C6-C22 fatty acids and C8-C22 alcohols, capric acid, caprylic acid, lauric acid, myristic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, behenic acid, and their corresponding pharmaceutically acceptable salts and derivatives.
20. The polymer as used in claim 16 is selected from cellulose derivatives like hydroxypropyl methyl cellulose, hydroxylpropyl cellulose, carboxymethyl cellulose, preferably as sodium or calcium salt, hydroxyethyl cellulose, polyvinyl pyrrolidone, co-polymers comprising vinyl pyrrolidone and vinyl acetate units, poly(oxyethylene) alkyl ether, polyethylene glycol, co-block polymers of ethylene oxide, and propylene oxide, polyvinyl alcohol, polyvinyl alcohol derivatives, polyethylene glycol, and polyethylene glycol derivatives.
PCT/IB2016/051233 2015-03-09 2016-03-04 Compositions containing a thrombin inhibitor WO2016142821A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1144CH2015 2015-03-09
IN1144/CHE/2015 2015-03-09

Publications (2)

Publication Number Publication Date
WO2016142821A2 true WO2016142821A2 (en) 2016-09-15
WO2016142821A3 WO2016142821A3 (en) 2016-11-03

Family

ID=56879305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/051233 WO2016142821A2 (en) 2015-03-09 2016-03-04 Compositions containing a thrombin inhibitor

Country Status (1)

Country Link
WO (1) WO2016142821A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019014712A (en) * 2017-07-03 2019-01-31 エルメッド エーザイ株式会社 Stable dabigatran formulation
WO2019004979A3 (en) * 2017-05-10 2019-04-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
WO2019004980A3 (en) * 2017-05-10 2019-04-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
WO2021150187A1 (en) * 2020-01-20 2021-07-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule-in-capsule comprising dabigatran etexilate
EP3787624A4 (en) * 2018-05-04 2022-03-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule-in-capsule compositions of dabigatran etexilate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201400737A1 (en) * 2011-12-22 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
EP2740471B1 (en) * 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019004979A3 (en) * 2017-05-10 2019-04-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
WO2019004980A3 (en) * 2017-05-10 2019-04-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
AU2018293361B2 (en) * 2017-05-10 2021-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Solid oral pharmaceutical compositions of dabigatran etexilate
JP2019014712A (en) * 2017-07-03 2019-01-31 エルメッド エーザイ株式会社 Stable dabigatran formulation
EP3787624A4 (en) * 2018-05-04 2022-03-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule-in-capsule compositions of dabigatran etexilate
WO2021150187A1 (en) * 2020-01-20 2021-07-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule-in-capsule comprising dabigatran etexilate

Also Published As

Publication number Publication date
WO2016142821A3 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
US20140044784A1 (en) Combined formulation with improved stability
WO2016142821A2 (en) Compositions containing a thrombin inhibitor
WO2002026210A2 (en) Proton pump inhibitor formulation
KR20090091084A (en) Controlled-release pharmaceutical formulation
US10363224B2 (en) Extended-release topiramate capsules
KR20150132399A (en) Pharmaceutical compositions comprising everolimus
WO2008083130A2 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2011140446A2 (en) Pharmaceutical formulations
JP2015500853A (en) Immediate release multi-unit pellet system
EP3793530A1 (en) Solid dispersion containing ritonavir
EP2740471A1 (en) Oral pharmaceutical composition comprising dabigatran etexilate
WO2014016754A2 (en) Pharmaceutical compositions of proton pump inhibitor
US10172878B2 (en) Extended-release topiramate capsules
WO2010041276A1 (en) Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof
MX2012011119A (en) Formulations of mazindol.
US20130143897A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
CA2804749C (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20140010883A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
SI22849A (en) Ropinirole preparation
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2015019256A1 (en) Pharmaceutical composition of vilazodone and processes of preparation thereof
KR20140104341A (en) Pharmaceutical composition consisting of sustained-release pellets
KR101072600B1 (en) Stable pharmaceutical composition comprising fluvastatin and method for preparing the same
EP2575820A1 (en) Controlled release dosage form comprising quetiapine
WO2010089760A2 (en) Controlled release, multiple unit pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16761163

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16761163

Country of ref document: EP

Kind code of ref document: A2